2024
Update on Biomarkers in Renal Cell Carcinoma.
Saliby R, Saad E, Kashima S, Schoenfeld D, Braun D. Update on Biomarkers in Renal Cell Carcinoma. American Society Of Clinical Oncology Educational Book 2024, 44: e430734. PMID: 38207251, DOI: 10.1200/edbk_430734.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal cell carcinomaCell carcinomaMetastatic renal cell carcinomaTumor intrinsic featuresImmune checkpoint inhibitorsRobust predictive biomarkersCheckpoint inhibitorsDurable responsesOverall survivalCare regimensPathological characteristicsPredictive biomarkersTherapeutic responseTreatment paradigmImmune systemHost factorsTranscriptional signatureGenomic alterationsTumor heterogeneityBiomarkersCarcinomaBiomarker discoveryInnovative technological approachesRegimens
2023
Novel Immune Therapies for Renal Cell Carcinoma Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes
Saad E, Saliby R, Labaki C, Xu W, Viswanathan S, Braun D, Bakouny Z. Novel Immune Therapies for Renal Cell Carcinoma Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes. Hematology/Oncology Clinics Of North America 2023, 37: 1027-1040. PMID: 37391289, DOI: 10.1016/j.hoc.2023.05.023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal cell carcinomaCell carcinomaMetastatic renal cell carcinomaCell death protein 1Programmed Cell Death Protein 1Novel immune targetsDeath protein 1Novel immune therapiesNovel immunotherapiesImmune therapyClinical evidenceImmune targetsImmune systemInhibitory stimuliTumoral cellsProtein 1ImmunotherapyPatientsCarcinomaImmunosuppressionTherapy
2019
State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era
Bakouny Z, Flippot R, Braun D, Lalani A, Choueiri T. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus 2019, 6: 37-40. PMID: 30827939, DOI: 10.1016/j.euf.2019.02.014.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCell carcinomaImmune systemTherapeutic resistanceMetastatic renal cell carcinomaImmune checkpoint inhibitorsMetastatic kidney cancerSubset of patientsPatient's immune systemImmunotherapy eraCheckpoint inhibitorsTreatment optionsKidney cancerPatientsTranslational approachTranslational researchImaging modalitiesCarcinomaTherapyTumorsNovel technological advancesSubstantial numberBiomarker discoveryBrief reportTumor spheroids